News
-
Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension
10/12/2012
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).
-
VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration For Development Of Novel TLR8 Agonist VTX-2337 With Celgene Corporation
10/3/2012
VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG) for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.
-
First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease
10/2/2012
Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
-
Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis
8/8/2012
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
Blinded Diagnostics Appoints Jon Klippel As VP, Business Development
7/13/2012
Blinded Diagnostics recently announced the expansion of their business development efforts by appointing Jon Klippel as the new Vice President of Business Development. Jon, a 25 year veteran of the medical device and diagnostics industry, will be working from the Saddle Brook office to provide point of care diagnostics solutions to pharmaceutical and biopharmaceutical clients.
- Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
-
Onyx Pharmaceuticals Initiates Phase 3 Kyprolis™ Head-To-Head Comparison Trial vs. Velcade® In Patients With Relapsed Multiple Myeloma
7/2/2012
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis™ (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib (Velcade®) with dexamethasone in patients with relapsed multiple myeloma.
- Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial 6/19/2012
-
Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis
6/5/2012
Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.
-
HIV Vaccine Trials Network Opens Enrollment For Phase 1 Trial Of GeoVax Labs' Second Generation HIV Vaccine
5/22/2012
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.